WithdrawnNot Applicable

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

Stopped: Study closed prior to enrollment of first participant

United States0Started 2022-04-01

Plain-language summary

A study to compare pain differences between using MedJet needle-free drug-delivery system with standard of care treatment for cutaneous T-cell lymphomas and cutaneous B-cell lymphomas in participants.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. \> 18 years of age
✓. Diagnosed with primary cutaneous lymphoma defined by either:
✓. The presence of plaque-type primary cutaneous lymphoma lesions with at least two plaques that are at least two cm² in areas of the trunk, buttocks, or extremities that are either:
✓. Able to give informed consent under IRB approval procedures

Exclusion criteria

✕. Known allergy or hypersensitivity to triamcinolone acetonide
✕. Known allergy to topical bexarotene or topical nitrogen mustard
✕. Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study.
✕. Inability to provide informed consent
✕. Diagnosis of erythrodermic mycosis fungoides or Sezary syndrome
✕. Use of topical corticosteroids to target lesions within 1 week prior to baseline visit
✕. Use of radiation therapy to target lesions within 1 week prior to baseline visit

What they're measuring

Pain measurement between the Med-Jet and standard of care treatment.

Timeframe: 1.5 Hour after the treatment

Trial details

NCT IDNCT05106192

SponsorCase Comprehensive Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Mycosis Fungoides of Skin (Diagnosis) trials